ライフサイエンスコーパス: guanabenz

1 for moxonidine versus -13.5+/-1.9 mm Hg for guanabenz).

2 e also excited by norepinephrine (50 ng) and guanabenz (10 microg) but not by clonidine (3 microg) or

3 ase at 6 months compared with those on 16 mg guanabenz (4/8; 50%), the historical cohort alone (21/49

4 Guanabenz, a metabolism-based irreversible inactivator o

5 Here we demonstrate that treating mice with guanabenz acetate (GA), an FDA-approved antihypertensive

6 gically Active Compounds and discovered that Guanabenz acetate (Wytensin), an FDA-approved drug forme

7 , experimental autoimmune encephalomyelitis, guanabenz alleviates clinical symptoms, which correlates

8 Moreover, guanabenz ameliorates relapse in relapsing-remitting exp

9 Guanabenz, an alpha2-agonist, prolonged baseline expirat

10 The cytoprotective effects of guanabenz (analogs) have been explained previously by th

11 ingly, robenidine is structurally similar to guanabenz (analogs), which are currently undergoing clin

12 in vivo, we have investigated the effects of guanabenz and N(G)-nitro-L-arginine in HEK 293 cells sta

13 have used two mechanism-based inactivators, guanabenz and NG-amino-L-arginine, to alter the heme/sub

14 The [(o-chlorobenzylidene)amino]guanidines (Guanabenz and Sephin1) have been proposed to exert prote

15 ee specific compounds, namely valproic acid, guanabenz, and a specific Caspase12 inhibitor, achieved

16 at least one adverse event was higher in any guanabenz arm than in the placebo arm, with higher dosin

17 nts did not significantly differ between the guanabenz arms and the placebo.

18 The treatment arms using 64 mg and 32 mg guanabenz, both alone and combined, reached the primary

19 the alpha2-adrenoceptor (alpha2-AR) agonist guanabenz, but not by the Ih-imidazoline receptor agonis

20 We show here that guanabenz, but not N(G)-nitro-L-arginine, caused the ina

21 demonstrate here that neither robenidine nor guanabenz disrupt the interaction between PPP1R15A and e

22 ver pure alpha(2)-adrenergic agonists (i.e., guanabenz) due to its lowered incidence of sedative side

23 ioral effects of low doses of moxonidine and guanabenz in C57Bl/6 mice in an exploratory arena.

24 stress response using the FDA-approved drug guanabenz increases oligodendrocyte survival in culture

25 ompared to saline-injected controls; whereas guanabenz induced only dose-responsive sedative-like beh

26 -2 adrenergic related side-effect profile of guanabenz is warranted.

27 Thus, guanabenz may be a promising therapeutic to minimize inf

28 :1 ratio to receive 64 mg, 32 mg or 16 mg of guanabenz or placebo daily for 6 months as an add-on the

29 complex and constitutive protein synthesis, guanabenz prolonged eIF2alpha phosphorylation in human s

30 Here we show that robenidine and guanabenz protect cells from a tunicamycin-induced unfol

31 by inhibition of Gadd34-PP1 phosphatase with guanabenz protects oligodendrocytes and partially rescue

32 obust preclinical findings demonstrated that guanabenz selectively inhibits endoplasmic reticulum str

33 We describe a small molecule, guanabenz, that bound to a regulatory subunit of protein

34 er signaling cascade, it was possible to use guanabenz to dose-dependently control expression of GLP-

35 In vivo, guanabenz treatment protects against oligodendrocyte los

36 When guanabenz was administered in the cuprizone model, in wh

37 AR involvement, the sedative-like effects of guanabenz were completely blocked by pretreatment with t

38 how the FDA-approved antihypertensive drug, guanabenz, which has a favorable safety profile and was

39 he clinically licensed antihypertensive drug guanabenz (Wytensin) activates a synthetic signal cascad